Boston Sci’s Wingspan Gets Limited Nat’l Coverage; Broad HDE Policy Will Wait
This article was originally published in The Gray Sheet
Executive Summary
Medicare will nationally cover intracranial stenting and angioplasty only in the controlled setting of FDA-cleared clinical trials, CMS says
You may also be interested in...
CMS Gives Boston Scientific Another Chance To Gain Brain Stent Coverage
CMS will reassess its national Medicare non-coverage policy on intracranial stenting and angioplasty, the agency announced Aug. 24
CMS Gives Boston Scientific Another Chance To Gain Brain Stent Coverage
CMS will reassess its national Medicare non-coverage policy on intracranial stenting and angioplasty, the agency announced Aug. 24
CMS Research Policy May Deny Coverage For Hundreds Of Device Trials
CMS' proposed Clinical Research Policy has generated widespread concern within the device industry about its potential to restrict Medicare support for clinical trials